Related Experiment Video
Updated: Aug 15, 2026

Feeding of Ticks on Animals for Transmission and Xenodiagnosis in Lyme Disease Research
Published on: September 1, 2013
Successful treatment of Lyme encephalopathy with intravenous ceftriaxone
E L Logigian1, R F Kaplan, A C Steere
1Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA. elogigian@mail.neurology.rochester.edu
Abstract:
The efficacy of intravenous ceftriaxone, 2 g per day for 30 days, was evaluated in a case series of 18 consecutive patients who met strict criteria for Lyme encephalopathy. Months to years after classic manifestations of Lyme disease, the 18 patients presented with memory difficulty, minor depression, somnolence, or headache. Sixteen (89%) had abnormal memory scores; 16 (89%) had cerebrospinal fluid (CSF) abnormalities, and all 7 patients tested had frontotemporal perfusion defects on single photon emission computed tomographic (SPECT) imaging. Six months after treatment, memory scores in the 15 patients who completed the study according to protocol were significantly improved (P<.01). In the 10 patients who had follow-up CSF analyses, total protein levels were significantly lower (P<.05). In the 7 patients who had SPECT imaging, posttreatment perfusion was significantly better (P<.01). Twelve to 24 months after treatment, all 18 patients rated themselves as back to normal or improved. We conclude that Lyme encephalopathy can be treated successfully with ceftriaxone.
Insights
Intravenous ceftriaxone effectively treated Lyme encephalopathy in 18 patients, improving cognitive function and neurological symptoms. Patients experienced significant recovery in memory, cerebrospinal fluid (CSF) abnormalities, and brain perfusion after a 30-day treatment course.
Area of Science:
- Neurology
- Infectious Diseases
- Pharmacology
Background:
- Lyme encephalopathy is a neurological complication of Lyme disease.
- Patients often present with cognitive and mood disturbances.
- Diagnostic challenges include memory deficits, CSF abnormalities, and perfusion defects.
Purpose of the Study:
- To evaluate the efficacy of intravenous ceftriaxone in treating Lyme encephalopathy.
- To assess treatment outcomes in patients with confirmed Lyme encephalopathy.
Main Methods:
- A case series of 18 patients with strict Lyme encephalopathy criteria.
- Treatment involved intravenous ceftriaxone (2 g/day for 30 days).
- Evaluations included cognitive testing, cerebrospinal fluid (CSF) analysis, and SPECT imaging.
Main Results:
- Significant improvement in memory scores (P<.01) after 6 months.
- Reduced CSF protein levels (P<.05) in 10 patients.
- Improved frontotemporal perfusion on SPECT imaging (P<.01) in 7 patients.
- All 18 patients reported normal or improved status 12-24 months post-treatment.
Conclusions:
- Intravenous ceftriaxone is a successful treatment for Lyme encephalopathy.
- Treatment leads to sustained neurological and cognitive recovery.
- Ceftriaxone offers a viable therapeutic option for this condition.
More Related Videos
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 15, 2014
09:46Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Rocky Mountain Spotted Fever
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Brain Abscess l: Introduction